When is the next results date for Vijaya Diagnost.?

No Upcoming Board Meetings

Has Vijaya Diagnost. declared dividend?

Yes, Vijaya Diagnostic Centre Ltd has declared a 100% dividend of ₹1 per share, with an ex-date of August 30, 2024. While the company has shown varying price returns over different periods, dividend returns have been relatively low.

Yes, Vijaya Diagnostic Centre Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 1<BR>- Ex-date: 30 Aug 2024<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -14.85%, the dividend return was 0%, resulting in a total return of -14.85%.<BR><BR>For the 1 year period, the price return was 19.05%, the dividend return was 0.12%, leading to a total return of 19.17%.<BR><BR>Over the 2 years period, the price return was 152.02%, the dividend return was 0.49%, which resulted in a total return of 152.51%.<BR><BR>In the 3 years period, the price return was 182.45%, the dividend return was 0.90%, culminating in a total return of 183.35%.<BR><BR>For the 4 years period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>In the 5 years period, there was also no change in price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Vijaya Diagnostic Centre Ltd has declared a dividend, the dividend returns over various periods have been relatively low compared to the price returns, indicating that while there is a dividend, the company's performance has varied significantly over time.

Who are the peers of the Vijaya Diagnost.?

Vijaya Diagnost.'s peers include Syngene Intl., Dr Lal Pathlabs, and Metropolis Health, among others. Its 1-year return is 18.52%, lower than Suven Life Scie. (161.32%) but higher than Metropolis Health (-11.47%).

Peers: The peers of Vijaya Diagnost. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Laxmi Dental, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest. Average management risk is present at Vimta Labs and Krsnaa Diagnost., while Below Average management risk is noted at Suven Life Scie. Growth is Excellent at Laxmi Dental, Good at Vimta Labs, and Average at Poly Medicure, Indegene, and the rest. Below Average growth is seen at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.32%, while the lowest is Metropolis Healt at -11.47%. Vijaya Diagnost.'s own 1-year return is 18.52%, which is significantly higher than Metropolis Healt but lower than Suven Life Scie. Additionally, the six-month return is negative for Syngene Intl., Metropolis Healt, and Krsnaa Diagnost.

Is Vijaya Diagnost. overvalued or undervalued?

As of August 1, 2022, Vijaya Diagnostics is considered very expensive and overvalued with a PE ratio of 69.56 and an EV to EBITDA of 36.94, trading at higher valuations than peers like Apollo Hospitals and Fortis Healthcare, despite outperforming the Sensex over the past year.

As of 1 August 2022, the valuation grade for Vijaya Diagnostics has moved from expensive to very expensive. The company is currently considered overvalued based on its high valuation metrics. Key ratios include a PE ratio of 69.56, an EV to EBITDA of 36.94, and a PEG ratio of 3.63, all of which indicate a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals Enterprise Ltd. has a PE ratio of 69.03 and an EV to EBITDA of 34.71, while Fortis Healthcare Ltd. shows a PE ratio of 68.71 and an EV to EBITDA of 37.55. These comparisons highlight that Vijaya Diagnostics is trading at a higher valuation than its peers in the healthcare services sector. Although the stock has outperformed the Sensex over the past year with a return of 19.95% compared to the Sensex's 7.55%, the overall valuation suggests that the stock is not a favorable investment at this time.

Who are in the management team of Vijaya Diagnost.?

As of March 2022, the management team of Vijaya Diagnost includes Sura Surendranath Reddy (Chairman & Executive Director), Sura Suprita Reddy (Managing Director & CEO), and several independent and non-executive directors. The team combines executive and non-executive roles to oversee the company's governance and management.

As of March 2022, the management team of Vijaya Diagnost includes the following individuals:<BR><BR>1. Sura Surendranath Reddy - Chairman & Executive Director<BR>2. Sunil Chandra Kondapally - Executive Director<BR>3. Geeta Reddy - Non-Executive & Non-Independent Director<BR>4. C S N Murthy - Independent Non-Executive Director<BR>5. Duvvuru Nageshwar Reddy - Independent Non-Executive Director<BR>6. Sekhar Prasad Singh - Independent Non-Executive Director<BR>7. Manjula Anagani - Independent Non-Executive Director<BR>8. Sura Suprita Reddy - Managing Director & CEO<BR><BR>This team comprises a mix of executive and non-executive members, with various roles contributing to the governance and management of the company.

What does Vijaya Diagnost. do?

Vijaya Diagnostic Centre Ltd is a leading diagnostic services provider in Southern India, established in 1981, with a market cap of INR 10,439 Cr and reported net sales of 1,732 Cr and net profit of 346 Cr for March 2025. The company has a P/E ratio of 73.00 and a return on equity of 18.08%.

Overview:<BR>Vijaya Diagnostic Centre Ltd is a leading provider of diagnostic services in the healthcare services industry and operates within the mid-cap market segment.<BR><BR>History:<BR>Incorporated in 1981, Vijaya Diagnostic Centre has established itself as the largest integrated diagnostic chain in Southern India. The latest quarterly results reported are for March 2025, showcasing the company's ongoing growth and commitment to quality services.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,732 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 346 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 10,439 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 73.00<BR>- Industry P/E: 59<BR>- Dividend Yield: 0.10%<BR>- Debt Equity: 0.11<BR>- Return on Equity: 18.08%<BR>- Price to Book: 13.15<BR><BR>Contact Details:<BR>No Company Details Available.

Who are the top shareholders of the Vijaya Diagnost.?

The top shareholders of Vijaya Diagnost include promoters holding the majority, with Surendranath Reddy Sura as the largest individual shareholder at 32.3%. Mutual funds hold 23.55%, foreign institutional investors 19.56%, and the highest public shareholder is Nippon Life India Trustee Ltd at 5.82%.

The top shareholders of Vijaya Diagnost include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority of the shares are held by promoters, with Surendranath Reddy Sura being the largest individual shareholder, holding 32.3%. Mutual funds collectively hold 23.55% of the shares, while FIIs account for 19.56%. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 5.82%. Additionally, individual investors have a stake of 3.24%.

How big is Vijaya Diagnost.?

As of 24th July, Vijaya Diagnostic Centre Ltd has a market capitalization of 10,333.00 Cr, with recent net sales of 681.39 Cr and a net profit of 143.09 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Vijaya Diagnostic Centre Ltd has a market capitalization of 10,333.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 681.39 Cr, while the sum of Net Profit for the same period is 143.09 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 657.19 Cr, and Total Assets are valued at 979.83 Cr.

Are Vijaya Diagnost. latest results good or bad?

Vijaya Diagnostic's latest results show strong revenue growth with record net sales of ₹201.56 crores, up 10.17% year-on-year. However, profitability concerns arise from lower year-on-year net profit growth and compressed operating margins, leading to a cautious outlook.

Vijaya Diagnostic's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹201.56 crores for the quarter, reflecting a strong year-on-year growth of 10.17% and a sequential increase of 7.18%. This growth is attributed to expanding operations and improved utilization rates, indicating operational momentum.<BR><BR>However, there are concerns regarding profitability. While net profit increased by 12.15% quarter-on-quarter to ₹43.28 crores, the year-on-year growth of only 2.75% is considerably lower than the revenue growth rate. Additionally, operating margins have compressed to 40.60%, down from 41.54% a year ago, which raises questions about the company's ability to maintain profitability amid rising costs and competitive pressures.<BR><BR>Overall, the results highlight strong revenue growth but also underline challenges in maintaining margins, leading to a cautious outlook from investors.

How has been the historical performance of Vijaya Diagnost.?

Vijaya Diagnost has shown consistent growth over the past five years, with net sales increasing from 376.75 Cr in Mar'21 to 681.39 Cr in Mar'25, and profit after tax rising from 85.13 Cr to 143.79 Cr in the same period, indicating strong operational efficiency and financial performance.

Answer:<BR>The historical performance of Vijaya Diagnost shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Vijaya Diagnost's net sales have increased from 376.75 Cr in Mar'21 to 681.39 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising to 681.39 Cr in Mar'25 from 459.22 Cr in Mar'23. The total expenditure, excluding depreciation, also grew, reaching 408.17 Cr in Mar'25, up from 210.77 Cr in Mar'21. Operating profit (PBDIT) saw a significant rise, reaching 291.54 Cr in Mar'25 compared to 177.83 Cr in Mar'21, indicating improved operational efficiency. Profit before tax increased to 193.16 Cr in Mar'25 from 112.12 Cr in Mar'21, while profit after tax rose to 143.79 Cr from 85.13 Cr in Mar'21. The earnings per share (EPS) also improved significantly, reaching 14.01 in Mar'25 from 3.68 in Mar'21. On the balance sheet, total assets grew to 1,273.62 Cr in Mar'25 from 480.68 Cr in Mar'20, while total liabilities increased to 1,273.62 Cr from 480.68 Cr in Mar'20, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved to 224.00 Cr in Mar'25 from 106.00 Cr in Mar'20, although net cash outflow was recorded at -9.00 Cr in Mar'25. Overall, Vijaya Diagnost has demonstrated robust growth in sales, profits, and operational cash flow over the years.

Should I buy, sell or hold Vijaya Diagnost.?

Why is Vijaya Diagnost. falling/rising?

As of 03-Dec, Vijaya Diagnostic Centre Ltd's stock price is declining, currently at Rs 999.00, due to underperformance against its sector, a bearish trend indicated by moving averages, and reduced investor participation. The stock has shown poor long-term growth and high valuation, contributing to its current downward trajectory.

As of 03-Dec, Vijaya Diagnostic Centre Ltd's stock price is falling, currently at Rs 999.00, reflecting a decrease of Rs 13.05 or 1.29%. This decline is attributed to several factors. The stock has underperformed its sector by 0.39% today and has experienced a trend reversal after two consecutive days of gains. Additionally, it reached an intraday low of Rs 991.55, which is a 2.03% drop.<BR><BR>The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 55.33% compared to the 5-day average. <BR><BR>From a broader perspective, the stock has shown poor long-term growth, with net sales growing at an annual rate of only 13.10% and operating profit at 7.27% over the last five years. It has also underperformed the market over the past year, generating a return of -14.14% while the broader market (BSE500) has returned 2.66%. The company's high valuation, indicated by a PEG ratio of 5, further suggests that the stock is trading at a premium compared to its peers, which may deter potential investors. <BR><BR>Overall, these factors contribute to the stock's current decline.

Which are the latest news on Vijaya Diagnost.?

Is Vijaya Diagnost. technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by bullish indicators like the MACD and Bollinger Bands, though caution is advised due to some lingering bearish signals.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly chart and bullish Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish trend. However, the monthly MACD and KST remain mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish stance on both weekly and monthly charts, while the On-Balance Volume is mildly bearish, indicating mixed signals. Overall, the strength of the bullish trend is tempered by some bearish indicators, but the shift to mildly bullish suggests potential for further upside.